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Abstract
Hypercalcemia is one of the most common paraneoplastic syndromes in hospitalized malignancy patients. The aim 
of this study was to determine the clinical characteristics and treatment outcome in hypercalcemia of malignancy. This 
was a study using medical records of patients with malignancy hospitalized in the Departement of Internal Medicine, 
Dr. Hasan Sadikin Hospital Bandung between December 2008 and March 2011. Statistical analysis was performed 
by Wilcoxon and Mann-Whitney tests. There were 40 patients with hypercalcemia of malignancy, consisted of 22 
hematologic malignancies and 18 solid tumors. Disturbance of consiousness were found in 4, dehydration in 18, 
constipation in 6, and nausea and vomiting in 6 subjects. In 16 subjects, no symptoms were found. All subjects received 
rehydration with normal saline. Bisphosphonate was given in 26 subjects. The difference of decreasing ion calcium 
level, between the groups who were treated with or without bisphosphonate was 0.59 (0.01–1.17) mg/dL, p=0.0001. 
In conclusion, hematologic and solid tumors are found in about the same proportion in hypercalcemia associated 
malignancy. Treatment either with or without bisphosphonate shows good results. [MKB. 2014;46(2):111–17]
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Abstrak
Hiperkalsemia merupakan salah satu sindrom paraneoplasma yang sering ditemukan pada pasien keganasan. Tujuan 
penelitian ini untuk mengetahui karakteristik klinis dan respons terapi penderita dengan hiperkalsemia pada keganasan. 
Penelitian ini menggunakan data rekam medis pasien yang dirawat di Departemen Penyakit Dalam Rumah Sakit 
Dr. Hasan Sadikin Bandung periode Desember 2008–Maret 2011. Analisis statistik menggunakan Uji Wilcoxon. 
Dari 40 penderita dengan hiperkalsemia pada keganasan, didapatkan 22 keganasan hematologi dan 18 tumor padat. 
Gejala klinis yang ditemukan adalah gangguan kesadaran pada 4 subjek, dehidrasi pada 18 subjek, konstipasi pada 6 
subjek, mual dan muntah pada 6 subjek. Pada 16 subjek tidak ditemukan gejala. Semua subjek mendapatkan rehidrasi 
dengan NaCl 0,9%. Dua puluh enam subjek mendapat terapi bisfosfonat. Perbedaan penurunan kadar kalsium ion 
antara kelompok yang mendapatkan bisfosfonat dan tidak adalah 0,59 (0,01–1,17) mg/dL, p=0,0001. Simpulan, 
proporsi keganasan penyebab hiperkalsemia hampir sama antara keganasan hematologi dan tumor padat. Terapi 
rehidrasi dengan NaCl 0,9% tanpa atau disertai bisfosfonat memberikan hasil yang baik. [MKB. 2014;46(2):111–17]
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Introduction
Malignancy adversely affects the bone as well as 
mineral metabolism through a broad spectrum of 
mechanisms. While focal osteolysis in metastasis 
sites is the most common skeletal manifestation of 
cancer, systemic effects such as hypercalcaemia or 
diffuse osteopenia are also common. Neoplasma 
can alter calcium homeostasis indirectly through 
the production of endocrine factors resulting 
in humoral hypercalcemia of malignancy. The 
mechanisms that are thought to be important 
during the development of hypercalcemia include 
bone-resorbing cytokines; parathyroid hormone-
related peptide secreted by the tumor that binds to 
parathyroid hormone receptors; tumor-mediated 
calcitriol production; and, occasionally, ectopic 
parathyroid hormone secretion.1-3 
Malignancy is one of the most common 
causes of hypercalcemia in hospitalized patients. 
In addition, hypercalcemia is one of the more 
common paraneoplastic syndromes.1 In overall, 
hypercalcemia of malignancy (HCM) occurs in 
10–20% of all patients with malignancy. As a 
paraneoplastic syndrome, HCM is commonly 
seen in association with multiple myeloma (MM) 
and breast, lung, renal and ovarian neoplasms. 
Hypercalcemia complicates 20–40% of cases of 
MM.3
The management of patients with HCM 
depends on the  severity of  symptoms and  the 
degree of hypercalcemia.3 Even though control of 
hypercalcemia is usually successful, the presence 
of  this complication is associated with a poor 
prognosis.1 Important therapeutic modalities 
include the following modalities: oral phosphates, 
saline hydration, gallium nitrate, calcitonin, 
corticosteroids, bisphosphonates, and dialysis.3,4
Currently, there is no study on the clinical 
characteristics and treatment of hypercalcemia 
of malignancy in Dr. Hasan Sadikin Hospital 
Bandung. The aim of this study was to obtain 
information about the clinical characteristics 
and treatment outcome in hypercalcemia of 
malignancy. This study results could be used 
to improve recognition and management of the 
hypercalcemia of malignancy.
Methods
This is a study using medical record of patients 
with malignancy who were hospitalized at the 
Departement of Internal Medicine, Dr. Hasan 
Sadikin Hospital Bandung during the period of 
December 2008–March 2011. Inclusion criteria 
were age above 14 years old, had hematologic 
malignancy or solid tumor confirmed through 
histopathologic analysis. Patients with acute or 
chronic renal failure, granulomatous disorders, 
adrenal insuffuciency, and thyrotoxicosis as well 
as those with thiazides consumption were not 
eligible for this study. 
The data was presented as frequency and 
median. The ionized calcium level before and 1 
day after bisphosphonate treatment was analyzed. 
The difference between ion calcium level before 
and after treatment was calculated by Wilcoxon 
test. The difference in the changes of ion calcium 
between subjects treated with biophosphonate 
and those who did not receive bisphosphonate 
was calculated by Mann–Whitney test.
Results
There were 40 subjects with hypercalcemia of 
malignancy, consisted of 22 with hematologic 
malignancies and 18 with solid tumors. Among 
subjects with hematologic malignancies, 15 were 
found with malignant lymphoma, followed by 
seven subjects with myeloma multiple. Among 
all solid tumors, most were found in the breast, 
followed by lung, head and neck cancer, i.e., 7, 
5 and 3 respectively. Prostate, pancreas and renal 
cell carcinomas were found in 1 subject for each 
cancer type. 
The changes in ion calcium level before and 
after treatment were available in 29 subjects 
(Table 3). The difference in the decreasing ion 
calcium level between the group who received 
bisphosphonate and not was 0.59 (0.01–1.17) 
mg/dL, p=0.0001. 
Elevation of ion calcium level in our study 
subjects was mild in 14, moderate in 4, severe in 
11, and life threatening in 11 subjects. Among 11 
subjects with life threatening HCM, no symptom 
was found in 4, dehydration was found in 3, 
loss of consciousness in 2 and constipation in 1 
subject. There was no cardiac arrest in all our 
subjects. Among 16 subjects without symptoms, 
we found mild, severe and life threatening HCM 
in 8, 4 and 4 subjects, respectively.
Discussion
Among all causes of hypercalcemia, primary 
hyperparathyroidism and malignancy are the most 
common, accounting for more than 90% of cases.4 
Hypercalcemia has been reported to occur in up 
to 20–30% of patients with cancer at some time 
during the course of their disease. Hypercalcemia 
leads to a progressive mental impairment, which 
include coma, as well as renal failure. In patients 
with cancer, these complications are particularly 
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common terminal events. The detection of 
hypercalcemia in patients with cancer signifies a 
very poor prognosis with approximately 50% of 
such patients die within 30 days.5 Hypercalcemia 
associated with cancer can be clasified into four 
types (Table 4).
In our study, there were 40 subjects with 
hypercalcemia of malignancy (HCM), consisted 
of 22 (55%) hematologic malignancies and 18 
(45%) solid tumors. Among the hematologic 
malignancy, malignant lymphoma was found in 
fifteen subjects, followed by seven subjects with 
myeloma multiple. Our result was about the same 
as the previous report.3 Among patients with 
skeletal involvement, HCM is most common in 
patients with multiple myeloma, affecting 30% to 
more than 80% of these patients.7 It is the most 
common cause of hypercalcemia in the inpatient 
setting. It occurs in patients with both solid tumors 
and hematologic malignancies. The most common 
cancers associated with hypercalcemia are breast 
and lung cancer and multiple myeloma.8,9 
Among 18 subjects with solid tumor, the most 
frequent was breast cancer, followed by lung, 
head and neck in 7, 5 and 3 subjects respectively. 
Prostate, pancreas and renal cell carcinomas 
were found in one subject for each cancer type. 
Hypercalcemia of malignancy is rare in patients 
with prostate cancer.7 Our study only found 1 
prostate cancer subject with HCM. 
Patients with HCM may present with wide 
range of symptoms, but the development and 
severity of symptoms do not appear to be strictly 
correlated with the serum calcium levels. The 
rapidity of onset is more likely to correlate with 
the symptom severity rather than the degree of 
hypercalcemia.10 
The early symptoms of HCM are mild and 
can be difficult to distinguish from those of 
underlying disease or the side effects of cancer 
therapy. Recognition of the early symptoms of 
HCM is vital because, if left untreated, it can 
progress rapidly and may become severe of 
life threatening. Progression of HCM can be 
prevented with apropriate measures, including 
hydration, anticancer therapy, and treatment with 
bisphosphonates. 7,11,12 
Hypercalcemia is, in almost all patients, due 
to an elevation in the physiologically important 
ionized (or free) calcium concentration. However, 
40–45% of the calcium in serum is bound to 
protein, principally albumin.13 
Elevation of ion calcium level in our study 
subjects were mild in 14, moderate in 4, severe 
in 11 and life threatening in 11 subjects. Among 
eleven subjects with life threatening HCM, no 
symptom was found in 4, dehydration in 3, loss of 
Table 1 Subjects Characteristics
Characteristics
Age (years)
Median 55.5 
Range 14–74 
Sex
Male 21 
Female 19 
Malignancy
Hematologic 22 
Solid tumor 18 
Ion Calcium level (mg/dL)
On admission (mg/dL) 6.9 (5.39–10.48) 
After treatment (mg/dL) 5.73 (4.39– 8.37)*
Severity of HCM 
Mild (>6 mg/dL) 14 
Moderate (>6.4 mg/dL) 4 
Severe (>6.8 mg/dL) 11 
Life threatening (>7.4 
mg/dL) 11 
Treatment
 Bisphosphonates 26 
No bisphosphonates 14 
Bone metastase
Yes 19 
No 21 
Renal impairment
 Yes 21
 No 19 
Chemotherapy
 Yes 15 
  No 25
*only available in 29 subjects, HCM: hypercalcemia of 
  malignancy
Table 2  Clinical Manifestation of
  Hypercalcemia
Clinical Manifestations n
No symptom 16
Disturbance of 
consiousness
4
Dehydration 18
Constipation 6
Nausea and vomiting 6
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consciousness in 2 and constipation in 1 subject. 
There was no cardiac arrest in all our subjects. 
Among 16 subjects without symptoms, we found 
mild, severe and life threatening HCM in 8, 4 
and 4 subjects, respectively. Our results showed 
wide variety of symptoms and HCM level. These 
results were consistent with the previous study 
that reported HCM  may present with wide range 
of symptoms but the development and severity of 
symptoms do not appear to be strictly correlated 
with serum calcium levels.7,12 
Treatment of HCM revolves around these 
two principles, i.e. treatment of the underlying 
malignancy along with the reduction of the serum 
calcium level.6 The ultimate treatment of HCM 
is eradication of the underlying cancer. However, 
cure is frequently not possible and in patients with 
symptomatic or life–threatening hypercalcemia, 
therapy must be aimed specifically againts the 
mediating mechanisms. The presence of increased 
osteoclastic bone resorption is seen in essentially 
every patient with HCM and, therefore, a key target 
for treatment and prevention of hypercalcemia. 
Two of these mechanisms in particular, increased 
osteoclastic bone resorption and increased renal 
tubular calcium reabsorption, are common to 
most patients with HCM, even though those cases 
not associated with parathyroid hormone related 
peptide (PTHrP) production. Medical therapy is, 
therefore, aimed at inhibiting bone resorption and 
promoting renal calcium excretion. 1,11 
Evidence–based therapies for management 
include intravenous crystalloid fluids with or 
without loop diuretics, bisphosphonates, calcitonin, 
Table 3 Changes of Ion Calcium Level Before and After Treatment
Ion Calcium Level (mg/dL) p
Before Treatment After Treatment Changes
All subjects 7.31 5.7 1.43 0.0001*
(5.6–10.48) (4.39–8.33) (0.45–3.67)
Bisphosphonate
Treatment
Yes
7.32            5.57 1.68 0.0001*
 (5.6–10.48) (4.39–8.37) (0.53–3.67)
No
6.88 6.06 1.04
(5.63–8.75) (4.5–7.7) (0.45–2.46)
 *Wilcoxon test; **Mann Whitney test: the difference of decreasing ion calcium level, between the group who received 
    bisphosphonate and not
Table 4  Type of Hypercalcemia Associated with Cancer* 
Type Frequency       (%) Bone Metastases Causal Agent Typical Tumors
Local osteoltic 
hypercalcemia 20 Common, extensive
Cytokine, 
chemokines, PTHrP
Breast cancer, 
multiple myeloma, 
lymphoma
Humoral hypercalcemia 
of malignancy 80 Minimal or absent PTHrP
Squamous–cell 
cancer, renal, ovarian, 
renal, ovarian, 
endometrial, HTLV–
associated lymhoma, 
breast cancer
1,25(OH)2D–secreting 
lymphoma <1 Variable 1,25(OH)2D Lymphoma (all types)
Ectopic 
hyperparathyroidism <1 Variable
Parathyroid 
hormone Variable
*PTHrP:parathyroid hormone related peptide; 1,25(OH)2D: 1,25 dihydroxyvitamin D; HTLV: human T–cell lymphotropic 
  virus.
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gallium nitrate and corticosteroids.3,4,6,14,15
The important general supportive measures 
include the removal of calcium from parenteral 
feeding solutions (a measure often overlooked); 
the discontinuation of oral calcium supplement  in 
enteral feeding solutions or in the form of  calcium 
tablets; the discontinuation of medications that 
may independently lead to hypercalcemia (e.g., 
lithium, calcitriol, vitamin D and thiazides); an 
increase in the weight–bearing mobility of the 
patient, if possible; and the discontinuation of the 
use of sedative drugs, including analgesic drugs 
if possible to enhance the patient’s mental clarity 
and promote wight–bearing ambulation.5 
Many hypercalcemia patients are presented 
with dehydration due to renal water concentrating 
defects (nephrogenic diabetes insipidus) and 
decreased oral hydration resulting from anorexia 
and nausea, vomiting, or both. The dehydration 
leads to a reduction in the glomerular filtration 
rate that further reduces the ability of the kidney 
to excrete the excess serum calcium. First, 
therefore, parenteral volume expansion should 
be initiated, with the administration of normal 
saline.5,11 This first step of therapy serves to 
rehydrate the patient while enhancing calciuresis 
by increasing the glomerular filtration rate and 
reducing the fractional  reabsorption of calcium 
and sodium.1,11 Although there are no randomized 
clinical trial to guide this therapy, in general 
practice normal saline is administered at a rate 
of 200–500 mL per hour, depending on the 
baseline level of dehydration and renal function, 
the patient’s cardiovascular status, the degree 
of renal impairment, and the severity of the 
hypercalcemia. These factors must be assessed 
with the use of careful clinical monitoring for 
physical finding that are consistent with fluid 
overload. The goals of treatment are to increase 
the glomerular filtration rate that will increase the 
filtered load of calcium which passes through the 
glomerulus into the tubular lumen and to inhibit 
calcium reabsorption in the proximal nephron 
(because saline itself is calciuretic).5 
The use of loop diuretics, such as furosemide, 
to enhance calcium excretion is frequently 
overemphasized in clinical practice. These agents 
may exacerbate fluid loss; therefore, their use 
should be limited to the volume–repleted patient 
and only then with close monitoring of volume 
status. Hydration alone rarely results in full 
resolution of hypercalcemia, however and more 
aggresive therapies are usually needed.1 
Intravenous bisphosphonates are by far 
the best studied, the safest and most effective 
agents for use in patients with hypercalcemia 
associated with cancer.5 Bisphosphonate are 
currently the mainstay for long-term treatment of 
Table 5  Symptoms and Calcium Serum Concentration (CSC) Level 7 
HCM severity
Total 
Calcium Bone Metastases Ca Ion Symptoms
(mmol/L) (mg/dL) (mg/dL)
Mild >3.0 >12 >6
Mild anorexia, 
nausea, weight 
loss, weakness, 
constipation, altered 
mental status
Moderate >3.2 >12.8 >6.4
Similar to mild 
HCM, with renal 
insufficiency and 
deposition of calcium 
in organs and tissues
Severe >3.4 >13.6 >6.8
Severe nausea 
and vomiting, 
dehydration, renal 
insufficiency and 
clouding and loss of 
consciousness
Live–threatening >3.7 >14.8 >7.4 Coma and cardiac arrest
Normal level of calcium: 2.0–2.7 mmol/L, 8.0–10.8 mg/dL. Normal level of calcium ion: 4.7–5.2 mg/dL., HCM: hypercalcemia 
of malignancy
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hypercalcemia and osteolytic bone disease. They 
have an affinity for bone surfaces undergoing 
active resorption and are released in the bone 
microenvirontment during remodelling.1,16 
Bisphosphonates are potent inhibitors of bone 
resorption and are the most effective therapy 
for HCM. Bisphosphonate compounds can be 
divided into two distinct pharmacological classes 
with different mechanisms of action depending 
on whether they contain a nitrogen atom in 
their side chains of non-nitrogen-containing 
bisphosphonates, which are the first generation 
bisphosphonates, that include etidronate and 
clodronate, are metabolized intracellularly to 
cytotoxic, non-hydrolyzable analogs of adenosine 
triphosphate (ATP) that may inhibit ATP-
dependent intracellular enzymes in osteoclasts. 
The nitrogen-containing bisphosphonates, which 
are second or third generation bisphosphonates 
that include pamidronate, alendronate, and 
ibandronate, inhibit protein prenylation which 
leads to loss of membrane localization of small G 
proteins such as Ras, Rho and Rac. Consequently, 
osteoclasts may undergo apoptosis.They are more 
potent than the first–generation bisphosphonates 
and have been used for the treatment of HCM.17
Bisphosphonate therapy should be initiated as 
soon as hypercalcemia is discovered, because a 
response requires 2–4 days and the nadir in serum 
calcium generally occurs within 4–7 days after 
therapy is initiated. Approximately 60–90% of 
patients have normal serum calcium levels within 
4–7 days and responses last for 1–3 weeks.5 In 
the United Sates, the two drugs that are approved 
by the Food and Drug Administration (FDA) and 
are currently considered the agents of chouce in 
the treatment of mild-to-severe hypercalcemia 
that is associated with cancer are pamidronate 
and zoledronate. Zoledronic acid is superior to 
pamidronat for the treatment of HCM with 4 mg 
as the recommended dose im the initial treatment 
of HCM and 8 mg for relapsed of refractory 
HCM.18-20 
In continental Europe, the United Kingdom 
and other countries, ibandronate and clodronate 
are also widely used.5 In our study, normal saline 
hydration was given to all subjects. Twenty six 
(65%) subjects received bisphosphonate. Due to 
financial problem, all patients could not received 
zoledronic acid and received clodronic acid 
instead. We had calcium ion level data before 
and after treatment in 29 subjects. All subjects 
had decreased ion calcium level after treatment. 
The ion calcium level in subjects received 
bisphosphonate before and after treatment were 
7.32 (5.6–10.48 mg/dL) and 5.57 (4.39–8.37 
mg/dL), respectively. The ion calcium level in 
subjects who did not received bisphosphonate 
was 6.88 (5.63–8.75 mg/dL) before the treatment 
and 6.06 (4.5–7.7 mg/dL) after the treatment. 
The difference of decreasing ion calcium level 
between subjects who received bisphosphonate 
and nor was 0.59 (0.01–1.17) mg/dL, p=0.0001.
In patients who have cancers that are likely 
to respond to therapy but in whom acute or 
chronic renal failure is present, aggressive saline 
infusion is not possible and other therapies such 
as bisphosphonates should be used with caution. 
In these circumstances, dialysis with dialysate 
containing litle or no calcium is a reasonable and 
highly effective option for selected patient.5 In 
our study, no patients underwent dialysis. The 
definite treatment (chemotherapy) was given in 
15 subjects.
In conclusion, the malignancy causing 
hypercalcemia was about the same proportion 
between hematologic and solid tumor. Among 
hematologic malignancy, malignant lymphoma 
followed by myeloma multiple. Among solid 
tumor, the most frequent one was breast cancer 
followed by lung cancer and head and neck 
cancer. Disturbance of consiousness, dehydration, 
constipation, nausea and vomiting were found. 
Treatment either with bisphosphonate or normal 
saline rehydration alone gave good result.
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